Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. - Wikidata - awgldk - TriplyDB

Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy.

Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy.

http://www.wikidata.org/entity/Q37360585

about

The Epigenomics of Embryonic Pathway Signaling in Colorectal Cancer.The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.Translating clinical research of Molecular Biology into a personalized, multidisciplinary approach of colorectal cancer patients Downregulation of LncRNA-RP11-317J10.2 promotes cell proliferation and invasion and predicts poor prognosis in colorectal cancer.Bax/Tubulin/Epithelial-Mesenchymal Pathways Determine the Efficacy of Silybin Analog HM015k in Colorectal Cancer Cell Growth and Metastasis.Innovative Disease Model: Zebrafish as an In Vivo Platform for Intestinal Disorder and Tumors.ALDH1A inhibition sensitizes colon cancer cells to chemotherapy.Myotubularin-related phosphatase 3 promotes growth of colorectal cancer cells

P2860

Q33705036-F6056332-D85D-4CAD-B5E6-1978161863E3 Q33912171-F1AB7B9F-730A-4C53-A0FB-7C200D7C73A6 Q37640727-9117FA34-2505-4682-AD3C-0F94B9C3918D Q47599561-EC8FA364-A7E7-46E4-8B9B-6FA12631A540 Q55070865-62ED38D1-7015-4040-A2D8-10F0F2721D0A Q55121561-5BB0789C-EEF1-4FE6-96C8-A648E46AF0D7 Q55426073-1F0A1D29-7A19-4C1F-9F57-F4BAE7251CDB Q59100713-EA49C06C-9E64-4C0F-BEB0-2F96F8B999FF

P2860

Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy.

http://www.wikidata.org/entity/Q37360585

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 September 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Evolvement of the treatment pa ...... motherapy to targeted therapy.

@en

Evolvement of the treatment pa ...... motherapy to targeted therapy.

@nl

type

label

Evolvement of the treatment pa ...... motherapy to targeted therapy.

@en

Evolvement of the treatment pa ...... motherapy to targeted therapy.

@nl

prefLabel

Evolvement of the treatment pa ...... motherapy to targeted therapy.

@en

Evolvement of the treatment pa ...... motherapy to targeted therapy.

@nl

P1433

Q37360585-2814B1A3-8192-45F5-A657-D340074E8A16

P1476

Q37360585-3A1A743E-D2D2-4061-9A52-A8380C5D8CC5

P2093

Q37360585-557BDE47-DD95-4404-8C01-9816A738F97E

Q37360585-D73B8A11-CD3A-4940-B0AA-B772EADBFDB5

P2860

Q37360585-03348A35-A0F1-45C3-833B-99625F8296AA

Q37360585-0842FA3C-0128-40F8-B17D-D7813D49F739

Q37360585-11FA412F-0D54-4FCF-B091-AA46850FC32B

Q37360585-17EA4E3D-0992-412F-83BF-2D5F666E12D8

Q37360585-1AEE9C2D-B0C3-494B-AD65-56116EDC7841

Q37360585-20FE5CD7-2ABC-47CA-9EA3-6BE2E38A382B

Q37360585-251A7FBD-E451-4B3E-B8EF-AC186081E190

Q37360585-273CAEE5-210D-424B-BE2C-ECD2DC1EC24E

Q37360585-3C52B101-0D10-45D3-8849-6DD88DC91D32

Q37360585-3DBD5472-F45A-4320-91EF-A46AF6DF38F0

P304

Q37360585-8A119548-738E-43A9-94D6-B3A266F0C559

P31

Q37360585-FDB1FB98-0B57-492E-82DC-1EB7915BEEAA

P356

Q37360585-74B6B165-809C-4921-A986-775D22106DA9

P433

Q37360585-49745D8D-0AC1-48E1-8FED-0FA421B15FA7

P478

Q37360585-C3FD1480-633B-44BA-92E7-89A4F4CB88A1

P577

Q37360585-233DD780-F833-4982-943E-BB04B4CB7245

P698

Q37360585-7A87584D-F0F2-430A-A7D1-768422A52D26

P921

Q37360585-3844FA1C-A534-439B-8F69-13AF3DAA7A00

P932

Q37360585-BF71DFAE-783A-4CAA-A2F9-2E7F6E0CC7F7

P356

J.CRITREVONC.2011.08.006

P1433

Critical Reviews in Oncology Hematology

P1476

Evolvement of the treatment pa ...... motherapy to targeted therapy.

@en

P2093

Sanjay Goel

http://www.w3.org/2001/XMLSchema#string

Santiago Aparo

http://www.w3.org/2001/XMLSchema#string

P2860

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

P304

47-58

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CRITREVONC.2011.08.006

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21944740

http://www.w3.org/2001/XMLSchema#string

P921

P932

3849106

http://www.w3.org/2001/XMLSchema#string